Literature DB >> 16461565

Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer.

K A Voutilainen1, M A Anttila, S M Sillanpää, K M Ropponen, S V Saarikoski, M T Juhola, V-M Kosma.   

Abstract

OBJECTIVE: To clarify the prognostic role of E-cadherin and beta- and gamma-catenins, and their relation to CD44 in epithelial ovarian carcinoma.
METHODS: The expression of E-cadherin and beta- and gamma-catenins was analysed immunohistochemically in 305 primary epithelial ovarian cancers and 44 metastases, and related to CD44 expression, clinicopathological factors, and the patients' survival.
RESULTS: Reduced cell surface expression of E-cadherin, beta-catenin, and gamma-catenin was particularly frequent in serous and endometrioid histological types. Reduced cell surface expression of E-cadherin and beta-catenin was also associated with poor differentiation. Nuclear positivity of beta-catenin was associated with high CD44 expression, endometrioid histology, and local stage of the tumour, whereas nuclear gamma-catenin expression was associated with serous histology and poor differentiation. In the univariate analysis, preserved cell surface beta-catenin expression in the whole study material and nuclear expression of beta- and gamma-catenins in the subgroup of endometrioid ovarian cancers were predictors of better 10 year disease related survival. Preserved cell surface expression of E-cadherin and beta-catenin predicted favourable recurrence-free survival. These statistical significances were not retained in multivariate analysis.
CONCLUSIONS: The correlation between nuclear beta-catenin and CD44 indicates that beta-catenin may regulate the transcription of CD44 in epithelial ovarian cancer. E-cadherin-catenin complex members are associated with the prognosis of patients with epithelial ovarian cancer, but these univariate associations were not strong enough to compete for significance with the traditional clinicopathological factors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16461565      PMCID: PMC1860287          DOI: 10.1136/jcp.2005.029876

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  51 in total

1.  Immunoreactive E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, and patients' survival.

Authors:  K Endo; T Ueda; J Ueyama; T Ohta; T Terada
Journal:  Hum Pathol       Date:  2000-05       Impact factor: 3.466

2.  gamma-catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of beta-catenin.

Authors:  F T Kolligs; B Kolligs; K M Hajra; G Hu; M Tani; K R Cho; E R Fearon
Journal:  Genes Dev       Date:  2000-06-01       Impact factor: 11.361

3.  Elevated expression of E-cadherin and alpha-, beta-, and gamma-catenins in metastatic lesions compared with primary epithelial ovarian carcinomas.

Authors:  Tsutomu Imai; Akiko Horiuchi; Tanri Shiozawa; Ryosuke Osada; Norihiko Kikuchi; Satoshi Ohira; Kenji Oka; Ikuo Konishi
Journal:  Hum Pathol       Date:  2004-12       Impact factor: 3.466

4.  High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer.

Authors:  M A Anttila; R H Tammi; M I Tammi; K J Syrjänen; S V Saarikoski; V M Kosma
Journal:  Cancer Res       Date:  2000-01-01       Impact factor: 12.701

5.  E-Cadherin complex protein expression and survival in ovarian carcinoma.

Authors:  B Davidson; W H Gotlieb; G Ben-Baruch; J M Nesland; M Bryne; I Goldberg; J Kopolovic; A Berner
Journal:  Gynecol Oncol       Date:  2000-12       Impact factor: 5.482

6.  beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome.

Authors:  C Gamallo; J Palacios; G Moreno; J Calvo de Mora; A Suárez; A Armas
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

7.  Expression and prognostic value of alpha-, beta-, and gamma-catenins indifferentiated thyroid carcinoma.

Authors:  J Böhm; L Niskanen; K Kiraly; J Kellokoski; M Eskelinen; S Hollmen; E Alhava; V M Kosma
Journal:  J Clin Endocrinol Metab       Date:  2000-12       Impact factor: 5.958

8.  E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions.

Authors:  B Davidson; A Berner; J M Nesland; B Risberg; H S Berner; C G Tropè; G B Kristensen; M Bryne; V Ann Florenes
Journal:  J Pathol       Date:  2000-12       Impact factor: 7.996

9.  Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas.

Authors:  J Palacios; C Gamallo
Journal:  Cancer Res       Date:  1998-04-01       Impact factor: 12.701

10.  Mutational analysis of beta-catenin gene in Japanese ovarian carcinomas: frequent mutations in endometrioid carcinomas.

Authors:  S Sagae; K Kobayashi; Y Nishioka; M Sugimura; S Ishioka; M Nagata; K Terasawa; T Tokino; R Kudo
Journal:  Jpn J Cancer Res       Date:  1999-05
View more
  26 in total

1.  Integrin regulation of beta-catenin signaling in ovarian carcinoma.

Authors:  Rebecca J Burkhalter; Jaime Symowicz; Laurie G Hudson; Cara J Gottardi; M Sharon Stack
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

2.  Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome.

Authors:  Geoffrey Kim; Ben Davidson; Ryan Henning; Junbai Wang; Minshu Yu; Christina Annunziata; Thea Hetland; Elise C Kohn
Journal:  Cancer       Date:  2011-08-25       Impact factor: 6.860

Review 3.  Translating next generation sequencing to practice: opportunities and necessary steps.

Authors:  Sitharthan Kamalakaran; Vinay Varadan; Angel Janevski; Nilanjana Banerjee; David Tuck; W Richard McCombie; Nevenka Dimitrova; Lyndsay N Harris
Journal:  Mol Oncol       Date:  2013-05-15       Impact factor: 6.603

Review 4.  E-cadherin's dark side: possible role in tumor progression.

Authors:  Fausto J Rodriguez; Laura J Lewis-Tuffin; Panos Z Anastasiadis
Journal:  Biochim Biophys Acta       Date:  2012-03-13

5.  Epithelial-mesenchymal interconversions and the regulatory function of the ZEB family during the development and progression of ovarian cancer.

Authors:  D I Wu; Lei Liu; Chengcheng Ren; Dan Kong; Pengqi Zhang; Xiaoming Jin; Tianzhen Wang; Guangmei Zhang
Journal:  Oncol Lett       Date:  2016-01-08       Impact factor: 2.967

6.  Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated AKT pathway.

Authors:  X Luo; Z Dong; Y Chen; L Yang; D Lai
Journal:  Cell Prolif       Date:  2013-08       Impact factor: 6.831

7.  Integrin beta3 down-regulates invasive features of ovarian cancer cells in SKOV3 cell subclones.

Authors:  Jie Chen; Jie Zhang; Yaoran Zhao; Jun Li; Maosun Fu
Journal:  J Cancer Res Clin Oncol       Date:  2008-12-23       Impact factor: 4.553

8.  PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL.

Authors:  Dalia El-Gamal; Katie Williams; Taylor D LaFollette; Matthew Cannon; James S Blachly; Yiming Zhong; Jennifer A Woyach; Erich Williams; Farrukh T Awan; Jeffrey Jones; Leslie Andritsos; Kami Maddocks; Chia-Hsien Wu; Ching-Shih Chen; Amy Lehman; Xiaoli Zhang; Rosa Lapalombella; John C Byrd
Journal:  Blood       Date:  2014-07-07       Impact factor: 22.113

9.  Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer.

Authors:  Branka Petrić Miše; Vesna Dobrić Telesmanić; Snježana Tomić; Dinka Šundov; Vesna Čapkun; Eduard Vrdoljak
Journal:  Pathol Oncol Res       Date:  2014-08-11       Impact factor: 3.201

Review 10.  Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression.

Authors:  Laurie G Hudson; Reema Zeineldin; M Sharon Stack
Journal:  Clin Exp Metastasis       Date:  2008-04-09       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.